Caeregen Therapeutics is focused on discovering and developing novel drug therapies which repair, restore, and protect damaged and diseased tissues by reactivating the pathways and signaling which accompanies normal cellular and tissue development
Incoming (2019) president, Club Jules Goninand past president, Retina Society−Developed Jetrea® from concept to clinic and sale to Thrombogenics ($250M)
PhD in Molecular Genetics and Microbiology (UF)− Director of Pediatric Retinal Disease Molecular Genetics Laboratory at Oakland University Eye Research Institute.
Associated Retinal Consultants, Royal Oak, MI−President, Pediatric Retinal Research Foundation−Extensive clinical trial experience.
Deep drug development back-ground, having ushered >25 drugs from various phases of development to commercial/clinical use−Former CEO/President, Multiple Myeloma Research Foundation.
Over 30 years conducting eye research. Spanning basic, translational and product development.
Expert in age-related macular degeneration Vice Chair for Research and founder of the Center for Advanced Vision Science, University of Virginia
Expert in diabetic retinopathy Director of Beetham Eye Institute at Joslin Diabetes Center, Harvard Medical School
Extensive innovations in intravitreal, gene and surgical adjuvant drug therapy. Founding Director of the Byers Eye Institute at Stanford
Discovered vascular endothelial growth factor (VEGF), Senior Deputy Director, Basic Science at UC San Diego
MD PhD Specialist in vitreoretinal diseases and surgery, including pediatric vitreoretinopathies Clinical professor at University of California at San Diego
Expert in retinopathy of prematurity and vascular growth mechanisms. Professor of Ophthalmology, Harvard Medical School
Learn more about investing in our innovation.
Data presented on promising activity of Noregen™, first potential regenerative therapy for retinal diseases Follows 1Q2022 U.S. FDA and EU EMA Orphan Drug Designation (ODD) for Noregen™ in F...
A Novel Regenerative Therapy For The Treatment Of Familial Exudative Vitreoretinopathy (FEVR) First potential FEVR therapy to obtain U.S. Food and Drug Administration Orphan Drug Designation Fol...
2021 Laureate Award Recognizes Exceptional Contributions in Overcoming Vision Loss November 11, 2021, Rochester, MI and New Orleans, LA – Caeregen Therapeutics, LLC, a Michigan-based, regenerative med...